ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Bristol-Myers Squibb and the Medical University of South Carolina have formed a research pact focused on fibrotic diseases such as scleroderma and renal fibrosis. MUSC says it has “unparalleled expertise” in fibrosis research. BMS’s drug pipeline includes two fibrosis treatments, and it has agreements with other organizations for potential drugs. Separately, the University of Texas System has joined a Sanofi program that funds R&D at academic institutions. Existing participants include Columbia University, Johns Hopkins University, and the University of Pennsylvania.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X